EVI5抗体;EVI5 Antibody—艾普蒂 新品

+ +

•  

   

     IHC-P analysis of brain tissue by EVI5 antibody (P15368) IHC-P was performed using sections of the formalin-fixed paraffin-embedded brain tissue;Result: Neuronal cells and are positively stained at cytoplasm and nuclei.    

  
  

**Background of EVI5 Antibody**

The EVI5 (Ecotropic Virus Integration Site 5) protein, encoded by the *EVI5* gene, is a conserved regulator implicated in cell cycle progression, membrane trafficking, and cellular signaling. Initially identified as a common integration site for murine leukemia viruses, *EVI5* gained attention due to its potential role in cancer and neurological disorders. The protein contains a RhoGAP-like domain, suggesting involvement in GTPase regulation, and interacts with Rab11. a key player in vesicle transport. EVI5 also regulates the anaphase-promoting complex/cyclosome (APC/C), ensuring proper mitotic exit by stabilizing its inhibitor, Emi1.

EVI5 antibodies are essential tools for studying these functions. They enable detection and localization of EVI5 in tissues or cultured cells via techniques like Western blotting, immunofluorescence, and immunohistochemistry. Dysregulation of EVI5 has been linked to cancers (e.g., glioblastoma, leukemia) and neurodegenerative conditions, driving interest in its therapeutic targeting. Commercial EVI5 antibodies are typically raised against specific epitopes, such as recombinant protein fragments or synthetic peptides, and validated for specificity across human, mouse, and rat models. Challenges include cross-reactivity with homologous proteins, emphasizing the need for rigorous validation. Research using these antibodies continues to unravel EVI5's dual roles in tumor suppression and oncogenesis, highlighting its context-dependent behavior in disease pathways.